Fintel reports that on May 4, 2026, Jefferies initiated coverage of COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) ...

Shares of the biotechnology company rocketed more than 50% this morning and were still higher by 41.2% at noon ET. Compass is ...

Does COMPASS Pathways PLC Sponsored ADR (CMPS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Compass Pathways (CMPS) shares printed a new year-to-date high on April 20 after President Donald Trump signed a landmark ...

Investors might want to bet on COMPASS Pathways PLC Sponsored ADR (CMPS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is COMPASS Pathways PLC Sponsored ADR (CMPS) one of those stocks right now? A quick ...

Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a ...

Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways is developing psilocybin as a treatment for depression. Viking ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...